Lords add to obviousness debate
01 September 2008
The House of Lords made its most important patent ruling in recent times when it clarified the test for obviousness in the UK. How have other courts dealt with this issue?
The House of Lords made its most important patent ruling in recent times on July 9, when it clarified the test for obviousness in the UK. In the closely watched case, Conor Medsystems Inc v Angiotech Pharmaceuticals Inc, the Lords upheld the validity of Angiotech's European patent for a paclitaxel-eluting stent and reversed the decisions of the UK Court of First Instance and the Court of Appeal. The lower courts had held the European patent to be invalid on the grounds of obviousness, though the validity of the same patent had been upheld in proceedings in The Netherlands.
While most patent laws worldwide exclude obvious inventions from patentability, courts have long struggled to decide how to set a test for obviousness. The latest decision in the UK is the fourth time that a high-level court in a major jurisdiction has addressed the controversial issue in the past two years.
Patent...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial